Insider Selling: CareDx, Inc (NASDAQ:CDNA) Insider Sells 34,231 Shares of Stock

CareDx, Inc (NASDAQ:CDNA) insider Alexander L. Johnson sold 34,231 shares of CareDx stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $33.55, for a total value of $1,148,450.05. Following the sale, the insider now directly owns 284,983 shares in the company, valued at $9,561,179.65. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

CareDx Trading Up 2.8 %

CDNA stock traded up $0.91 during midday trading on Wednesday, hitting $33.36. The company’s stock had a trading volume of 733,653 shares, compared to its average volume of 921,881. The company has a market cap of $1.74 billion, a PE ratio of -9.78 and a beta of 1.78. CareDx, Inc has a 12 month low of $4.80 and a 12 month high of $34.84. The firm’s 50-day moving average is $19.28 and its 200-day moving average is $13.79.

Analyst Upgrades and Downgrades

Several analysts have weighed in on CDNA shares. Stephens lifted their price objective on CareDx from $15.00 to $18.00 and gave the company an “overweight” rating in a research report on Monday, May 13th. BTIG Research raised CareDx from a “neutral” rating to a “buy” rating and set a $40.00 price target on the stock in a research report on Monday. Craig Hallum boosted their price target on CareDx from $22.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Raymond James cut CareDx from an “outperform” rating to a “market perform” rating in a research report on Monday, May 13th. Finally, The Goldman Sachs Group boosted their price target on CareDx from $16.00 to $26.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, CareDx presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.00.

Hedge Funds Weigh In On CareDx

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CDNA. Strs Ohio raised its stake in CareDx by 65.2% during the 4th quarter. Strs Ohio now owns 60,300 shares of the company’s stock valued at $723,000 after buying an additional 23,800 shares during the last quarter. Cetera Trust Company N.A purchased a new stake in CareDx during the 4th quarter valued at $142,000. Headlands Technologies LLC purchased a new stake in CareDx during the 4th quarter valued at $50,000. Jackson Creek Investment Advisors LLC purchased a new stake in CareDx during the 4th quarter valued at $1,455,000. Finally, Los Angeles Capital Management LLC raised its stake in CareDx by 138.9% during the 4th quarter. Los Angeles Capital Management LLC now owns 237,115 shares of the company’s stock valued at $2,845,000 after buying an additional 137,842 shares during the last quarter.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.